Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8060719 | 0.84 | KMT2A (0.60) | HTTKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL8044111 | 0.84 | KMT2A (0.60) | HTTKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL27795750 | 0.84 | KMT2A (0.60) | HTTKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL12920962 | 0.81 | KMT2A (0.57) | HTTKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL12946361 | 0.80 | KMT2A (0.57) | HTTKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL8045931 | 0.73 | KMT2A (0.60) | HTTKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL12920954 | 0.72 | KMT2A (0.70) | HTTKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL19658757 | 0.72 | HTT (0.71) | HTTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL14535437 | 0.72 | HTT (0.71) | HTTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL4862572 | 0.70 | HTT (0.69) | HTTKMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| WO-2009020580-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | HTT 502/4885KMT2A 3290/4885MEN1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.